Early RA Referral Clinics Work (9.18.2026) Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/ofGKCCNQnE https://t.co/fn0L4goAMT https://t.co/F8QKs7261x

QD Clinic: GLP-1s and History of Thyroid Cancer? Daric Mueller, PA-C, St. Clair Shores, MI, presents this case as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/rhsUNVIdQ4 https://t.co/mjHEWNIGqU

QD Clinic: Bariatric Surgery "Curing" Arthritis? Dr. Richard Conway, Dublin, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/YwtSkroMta https://t.co/tl8eSrvGhq

Obesity in Rheumatic Diseases: More than just a Comorbidity https://t.co/0QJ188HYSm https://t.co/3L09m2cowl

Metabolomic/proteomics w/ cardiac MRI & longitudinal outcomes in 488079 UK Biobank pts shows chronic systemic inflammation assoc w/ reduced LV volumes, incr CV risk (cytokines, GFs, IL-1, TNF as potential mediators) https://t.co/3woGOttKHz https://t.co/eJLkPyJe6U

Obesity and Gout: An Old Relationship with New Thoughts https://t.co/T71u9Ta4NS https://t.co/B7vUVqIBQE

🚨 Registration opens October 1! RheumNow Live 2027 returns January 30–31 for our 9th Annual CME Meeting. 📍 Dallas + Online 📅 January 30–31, 2027 🎓 High-impact CME. Expert faculty. Real-world rheumatology. The rheumatology meeting that sets the tone for the year ahead. https://t.co/PFZ37DlTQe

Systematic review 14 studies assessed Lung ultrasound (LUS) (vs HRCT) to detect RA-ILD (using threshold of ≥ 5 B-lines) found sensitivity was 86.8% (95% CI 80.1–91.4), specificity 75.4% (95% CI 62.3–85.1), and AUC 0.890 https://t.co/GlNpsPBwtS https://t.co/FJ6B5E5CWy

FORWARD is a Phase 4, OL trial in 51 refractory uncontrolled gout pts Rx w/ MTX plus higher doses pegloticase (16 or 30mg) IV q4wk. At 24-wk Responses similar 68% or 73%. ~31% of responders later had SUA >6. Confusing anti-Drug Ab results in this trial?? https://t.co/udjE7sXDm5 https://t.co/F8VGDAyJzb

Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved ≥1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ https://t.co/EdAqXfsjW0

Single center, DBRPCT of tofacitinib 11 mg/d vs PBO in 100 knee OA pts (KL Gr 1-2); At wk 12 there was NO significant differences betw groups in VAS Pain, or other outcomes-WOMAC, Oxford Knee Score, EQ-5D-5L, analgesic use https://t.co/VDtgY7hTm4 https://t.co/PveouQbI8r

Phenotypic cluster analysis of 134 CPPD pts from COLCHICORT & CHRONIC-CPPD European cohorts ID 4 Grps: 1) C1 monoarticular recurrent flares, older, W, ^CRP; 2) C2 monoarticular w persistent arthritis; 3) C3 polyarthritis lower CRP; 4) C4 polyarticular (spine/shoulder( & recurrent https://t.co/ghMCmDLCki

CLOAK study: 3 mos DBRPCT of Colchicine vs PBO (no NSAID) in 120 symptomatic KOA (KL gr 2/3) shows no benefit in VAS pain index knee after 3 mos. (but COL pts had signif change in some biomarkers hsCRP, β-NGF (p < 0.05); PGE2, IL-1ra, IL-8, and VEGF (p < 0.16). https://t.co/MPgLpr7LPP

17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vX https://t.co/EqRwpT8Sxo